CD34 and acute myeloid leukemia: When we compared the metabolic status of circulating CD34+ AML cells with the metabolic state of paired BM resident fractions, no significant differences were reported in puromycin levels (Supplementary Fig. 2a) or metabolic parameters (Fig. 2c).